| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/29/2009 | US20090028952 Hydroxy sulfonate of quinone compounds and their uses |
| 01/29/2009 | US20090028951 Compositions for Oral Administration of Sustained Release Glutathione, Methods for Their Production and Uses Thereof |
| 01/29/2009 | US20090028950 Granule dispersion composition, process for producing the same, and granular material and medicine |
| 01/29/2009 | US20090028949 Calcium phosphate-based adhesive formulation for bone filling with swelling properties |
| 01/29/2009 | US20090028948 Nanoparticle composition and methods of synthesis thereof |
| 01/29/2009 | US20090028947 Using of nanosilver in poultry, livestock and aquatics industry |
| 01/29/2009 | US20090028946 Photo-responsive delivery system |
| 01/29/2009 | US20090028945 Immunoisolative encapsulation system |
| 01/29/2009 | US20090028944 Pharmaceutical compositions comprising mesalamine |
| 01/29/2009 | US20090028943 Pharmaceutical compositions |
| 01/29/2009 | US20090028941 Pulsatile gastric retentive dosage forms |
| 01/29/2009 | US20090028940 Pharmaceutical compositions of rifaximin |
| 01/29/2009 | US20090028939 Solid Preparation |
| 01/29/2009 | US20090028938 Dosage forms with improved bioavailability |
| 01/29/2009 | US20090028937 Tablet comprising ornithine hydrochloride |
| 01/29/2009 | US20090028936 Tablets containing enrofloxacin and flavouring agents and/or flavours |
| 01/29/2009 | US20090028935 Carvedilol forms, compositions, and methods of preparation thereof |
| 01/29/2009 | US20090028934 Granular, gastro-resistant product based on niacin or derivates thereof and process for the production of such a product |
| 01/29/2009 | US20090028933 Compositions and methods for treating lymphoma |
| 01/29/2009 | US20090028932 Vaccine formulations for leishmania |
| 01/29/2009 | US20090028931 Liposomal compositions for parenteral delivery of agents |
| 01/29/2009 | US20090028930 Bruise amelioration composition and method of use |
| 01/29/2009 | US20090028929 Transdermal Patch |
| 01/29/2009 | US20090028928 Patch and patch preparation |
| 01/29/2009 | US20090028927 Poly(vinyl alcohol) - bacterial cellulose nanocomposite |
| 01/29/2009 | US20090028926 Method and mixture for in vivo photochemical cross-linking of collagen |
| 01/29/2009 | US20090028925 Novel Phosphinic Acid-Containing Thyromimetics |
| 01/29/2009 | US20090028922 Local Delivery Method and Composition |
| 01/29/2009 | US20090028918 Gynecological pharmaceutics- containing microspherical vascular suppository of sodium alginate and its preparation method |
| 01/29/2009 | US20090028916 Loaded Microspheres |
| 01/29/2009 | US20090028912 Materials for Dissolution-Controlled Release |
| 01/29/2009 | US20090028910 Methods for Fabrication Isolated Micro-and Nano-Structures Using Soft or Imprint Lithography |
| 01/29/2009 | US20090028904 Novel cochleate formulations |
| 01/29/2009 | US20090028890 encodes an HIV-1 MA polypeptide myristate binding site; capable of selectively eliciting a substantially th-1 immune response to HIV-1; vaccine |
| 01/29/2009 | US20090028814 High molecular weight medicine-containing preparation in powder form for administration through mucosa |
| 01/29/2009 | US20090028811 Personal Lubricant |
| 01/29/2009 | US20090028802 Organoleptically acceptable indole serotonin receptor agonist oral dosage formulations and methods of using the same |
| 01/29/2009 | US20090028801 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
| 01/29/2009 | US20090028800 Method of Treating Postpartum Depression and Aggression |
| 01/29/2009 | US20090028792 Nano-particle surface modification |
| 01/29/2009 | US20090025719 Pre-metered dry powder inhaler for moisture-sensitive medicaments |
| 01/29/2009 | US20090025713 Nebulised Antibiotics for Inhalation Therapy |
| 01/29/2009 | DE4497905B4 Verfahren zur Herstellung von Phencynonat-Hydrochlorid mit α-Konfiguration Process for preparing phencynonate hydrochloride with α-configuration |
| 01/29/2009 | DE102007034976A1 Arzneimittel zur transdermalen Anwendung bei Tieren For transdermal drug use in animals |
| 01/29/2009 | DE102007034682A1 Injection device for injection into biological tissue with injection syringe into organism, has actuating device with actuating element that forms abutment for piston device of injection syringe on guide device |
| 01/29/2009 | CA2695204A1 Methods for imaging using improved nanoparticulate contrast agents |
| 01/29/2009 | CA2694929A1 Pharmaceutical preparations comprising electrochemically activated hypochlorite solutions |
| 01/29/2009 | CA2694852A1 Microparticles comprising pcl and uses thereof |
| 01/29/2009 | CA2694512A1 Hyperthermia devices and their uses with nanoparticles |
| 01/29/2009 | CA2694479A1 Novel powderous medicaments comprising tiotropium and salmeterol and lactose as carrier |
| 01/29/2009 | CA2694466A1 Immunogenic polypeptides and monoclonal antibodies |
| 01/29/2009 | CA2694440A1 Controlled release interferon drug products and treatment of hcv infection using same |
| 01/29/2009 | CA2694408A1 Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
| 01/29/2009 | CA2694403A1 Topical antibiotic composition for the prevention of lyme disease |
| 01/29/2009 | CA2694386A1 Medicament for transdermal use on animals |
| 01/29/2009 | CA2694235A1 Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
| 01/29/2009 | CA2694122A1 Central administration of stable formulations of therapeutic agents for cns conditions |
| 01/29/2009 | CA2694083A1 Antigen-adjuvant compositions and methods |
| 01/29/2009 | CA2694054A1 Omega-3 fatty acid fortified composition |
| 01/29/2009 | CA2693888A1 Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
| 01/29/2009 | CA2693587A1 Metal complexes incorporated within biodegradable nanoparticles and their use |
| 01/29/2009 | CA2693235A1 Improvements relating to anti-hiv tablet formulations |
| 01/29/2009 | CA2693233A1 Improved pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof |
| 01/29/2009 | CA2693179A1 Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof |
| 01/29/2009 | CA2693166A1 Drug formulations having inert sealed cores |
| 01/29/2009 | CA2692892A1 Technology for the preparation of microparticles |
| 01/29/2009 | CA2691752A1 Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof |
| 01/29/2009 | CA2690829A1 Formulations of nonopioid and confined opioid analgesics |
| 01/28/2009 | EP2019141A2 Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines |
| 01/28/2009 | EP2019140A2 Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines |
| 01/28/2009 | EP2018875A1 Poorly-water-soluble pharmaceutical agent |
| 01/28/2009 | EP2018869A1 Licorice polyphenol preparation |
| 01/28/2009 | EP2018866A1 Pharmaceutical compositions containing voriconazole |
| 01/28/2009 | EP2018860A1 Duloxetine composition |
| 01/28/2009 | EP2018858A1 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic trioxide |
| 01/28/2009 | EP2018853A1 Pharmaceutical compositions comprising a HMG COA reductase inhibitor |
| 01/28/2009 | EP2018852A1 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 01/28/2009 | EP2018851A1 Enhanced formulations of lamotrigine |
| 01/28/2009 | EP2018850A1 Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof |
| 01/28/2009 | EP2018403A1 Water dispersible films for delivery of active agents to the epidermis |
| 01/28/2009 | EP2018186A2 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
| 01/28/2009 | EP2018172A2 Delivery of active agents using a chocolate vehicle |
| 01/28/2009 | EP2018160A2 Modified release formulations containing drug-ion exchange resin complexes |
| 01/28/2009 | EP2018159A2 Colonic drug delivery formulation |
| 01/28/2009 | EP2018158A1 New form of administration of racecadotril |
| 01/28/2009 | EP2018157A2 Controlled release formulation comprising anti-epileptic drugs |
| 01/28/2009 | EP2018156A1 Compositions and methods for treating b- cell malignancies |
| 01/28/2009 | EP2018155A1 Method for extemporaneous and reversible concentration of liposomes |
| 01/28/2009 | EP2018154A1 Hydrogel suspension and manufacturing process thereof |
| 01/28/2009 | EP2018153A1 Liquid oral compositions |
| 01/28/2009 | EP2018152A2 Pre-mixed, ready-to-use pharmaceutical compositions |
| 01/28/2009 | EP2018151A1 Parenteral formulation comprising proton pump inhibitor sterilized in its final container by ionizing radiation |
| 01/28/2009 | EP2018150A1 Pharmaceutical composition having reduced abuse potential |
| 01/28/2009 | EP2018103A2 Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear |
| 01/28/2009 | EP1715851B1 Consumer customized dosage forms |
| 01/28/2009 | EP1648473B1 Single dose fast dissolving azithromycin |
| 01/28/2009 | EP1553922B1 Salmeterol superfine formulation |
| 01/28/2009 | EP1499410B1 Preparation of small crystals |
| 01/28/2009 | EP1470826B1 Decoy-containing pharmaceutical compositions for the treatment of aneurysms |
| 01/28/2009 | EP1073416B1 Use of inhaled no as anti-inflammatory agent |